For most US biotech and healthcare startups, the funding stack looks like this: NIH SBIR Phase I ($323K non-dilutive feasibility grant) to de-risk the science, followed by NIH SBIR Phase II ($2.15M) for full development, layered with the federal Section 41 R&D tax credit (up to $500K/yr cash payroll offset for pre-revenue companies), and stacked with relevant state R&D credits (Massachusetts pays out 90% in cash for certified life sciences companies). The FDA OOPD program is the right fit for ultra-rare cancer therapeutics. NSF SBIR fits when your primary innovation is a device or platform technology, not a therapeutic. SBA 7(a) fills the facility and equipment financing gap that grants don't cover.
The biotech and healthcare federal funding landscape
The US federal government is, by a wide margin, the largest non-dilutive funder of early-stage life-sciences R&D in the world. NIH alone awards roughly $4 to $5 billion per year in life-sciences SBIR and STTR grants across its 27 institutes and centers. NIH represents approximately 50% of all SBIR dollars awarded by the entire federal government each year. The remaining half is split among DoD, NSF, DOE, USDA, and smaller agencies.
For biotech and healthcare companies specifically, the funding landscape organizes into four distinct tiers:
- Non-dilutive grant programs (NIH SBIR/STTR, NSF SBIR, FDA cooperative agreements) — cash awards with no equity taken, no repayment obligation
- Tax-based incentives (federal Section 41 R&D credit, state R&D credits) — reduce your effective tax burden or generate cash refunds against payroll taxes
- Loan programs (SBA 7(a), SBA 504) — debt financing for facilities, equipment, and working capital that grants don't cover
- Cooperative agreements (FDA OOPD, NIH U01) — federal partnerships where the agency co-investigates rather than simply funding
These four tiers are not mutually exclusive. A Massachusetts biotech company running NIH SBIR Phase I can simultaneously claim the federal Section 41 R&D credit (and apply it against payroll taxes as a pre-revenue QSB), claim the Massachusetts R&D credit and receive 90% back in cash as a certified life sciences company, and use an SBA 7(a) loan to finance the lab buildout NIH grants won't cover. Understanding how these layers stack — and in what sequence to apply for them — is where most founders leave money on the table.
| Program | Max Amount | Type | Receipt / Deadline |
|---|---|---|---|
| NIH SBIR Phase I | $323,090 | Grant (non-dilutive) | Sept 5 / Jan 5 / Apr 5 |
| NIH SBIR Phase II | $2,153,927 | Grant (non-dilutive) | Same 3-cycle cadence |
| NIH STTR Phase I | $323,090 | Grant (research partnership) | Sept 5 / Jan 5 / Apr 5 |
| NSF SBIR Phase I | $305,000 | Cooperative Agreement | 4–5 windows/year (pitch first) |
| FDA OOPD (ultra-rare cancers) | ~$500K/yr x 3 yrs | Cooperative Agreement (U01) | June 15, 2026 |
| Federal §41 R&D Credit (QSB) | $500K/yr payroll offset | Tax credit (refundable via payroll) | Annual tax return |
| SBA 7(a) Loan | $5,000,000 | Loan (government-guaranteed) | Rolling |
Here's what you need to know about the biotech funding landscape: these programs are not competitive in the way most founders fear. NIH SBIR is peer-reviewed by scientists, not by bureaucrats making arbitrary choices. A scientifically credible application addressing a genuine unmet need, submitted to the right institute, has a real 16 to 25% funding probability. The study section score determines your fate, and that score is almost entirely determined by scientific merit and commercial feasibility — factors you can control and prepare for.
NIH SBIR and STTR — the core funding source for biotech
NIH's Small Business Innovation Research and Small Business Technology Transfer programs together represent the dominant source of non-dilutive early-stage funding for biomedical companies. NIH awards roughly $2 to $2.5 billion per year in SBIR alone across its institutes. Understanding how the system works — particularly study sections and institute selection — is more valuable than any line-by-line application tip.
Phase I vs Phase II: what you're actually applying for
| Parameter | Phase I (R43) | Phase II (R44) |
|---|---|---|
| Award cap (total costs) | $323,090 | $2,153,927 |
| Period of performance | 6 months typical | 2 years (up to 3 with justification) |
| Purpose | Technical feasibility / proof-of-concept | Full R&D development toward commercialization |
| Prior award required | No | Yes — must have completed Phase I from NIH |
| Typical application hours | ~160 hours | ~220 hours |
| Success rate (system-wide) | 16–25% | 15–25% |
| Commercialization plan weight | Moderate | High — FDA pathway clarity expected |
A critical fact that trips up first-time applicants: Phase II is not an automatic continuation of Phase I. It is a fully competitive re-application submitted to the same NIH institute, peer-reviewed by a study section from scratch, and scored against that cycle's pool of Phase II applicants. A borderline Phase I score does not preclude a strong Phase II, and a perfect Phase I score does not guarantee Phase II funding. The Phase II review places significantly more weight on the commercialization plan: study sections increasingly expect FDA pathway clarity, identified manufacturing partners, and letters of intent from strategic partners or early customers.
How study sections and scoring actually work
A study section is a NIH peer review panel of 20 to 30 scientists who read, score, and discuss your application. Each application is assigned to a study section based on your research topic. Your score — expressed as a percentile rank — determines funding. Most institutes fund in roughly the top 20th percentile of scored applications in a given cycle, though this cutoff varies by institute and year.
NIH assigns applications to study sections within the Center for Scientific Review (CSR), or in some cases to institute-specific review groups. The study section reads your application before the meeting; two or three assigned reviewers provide written critiques; the full panel scores only applications that clear an initial triage (roughly the top 50%). The final score is an average of individual reviewer scores on a 1-to-9 scale (1 = best), multiplied by 10 to yield a 10 to 90 impact score. That impact score is converted to a percentile by comparing it to all applications scored in recent cycles.
Most institutes fund in roughly the top 20th percentile — meaning a percentile rank of 20 or lower. However, "paylines" vary: NCI's payline has been as strict as the 10th percentile in competitive years. NIMH, NIBIB, and some smaller institutes have been more generous. Always check your target institute's current payline on their website before submitting.
The five scoring criteria (Significance, Innovation, Approach, Investigators, Environment) are each scored 1 to 9, then combined into a single impact score. The Approach criterion carries the heaviest practical weight for SBIR applications — reviewers who doubt your technical feasibility will score it poorly regardless of how strong the rest of the application is.
Expert Deep-Dive: How to navigate NIH study sections and maximize your score
Before you write anything: email the Program Officer. NIH Program Officers (POs) are the scientific staff at each institute who manage the grants portfolio. Unlike most government funding staff, NIH POs are explicitly accessible to applicants before submission. A brief email — three paragraphs describing your technology, target patient population, and proposed Phase I aims — will typically receive a substantive reply within a week. The PO can tell you whether your project fits the institute's current priorities and, crucially, whether it fits the institute at all. This conversation costs two hours and can save 160+ hours on an application that would have been triaged or administratively rejected.
Institute selection is your single most important strategy decision. NIH SBIR is not a single competition — it is 27 separate competitions run by 27 separate institutes. Each institute funds different topic areas, has different paylines, and has different study section reviewers. A company working on a cancer diagnostic has natural homes at NCI, NIBIB (if it's an imaging device), and potentially NHLBI (if it's a cardiovascular cancer concern). Submitting to the right institute dramatically improves your odds because the reviewers in that study section will understand your science, your clinical context, and the commercial landscape.
The Approach section is where applications succeed or fail. Reviewers are scientists. They will scrutinize your experimental design, your statistical plan, and your go/no-go criteria. Vague aims ("we will characterize the protein's function") are scored more poorly than specific measurable aims ("we will demonstrate that the peptide inhibitor achieves IC50 below 10 nM in the X cell line assay by week 16"). Every aim needs a clear milestone and an explicit description of what happens if the milestone is not met.
Fast Track: combining Phase I and Phase II in one application. Some NIH institutes accept Fast Track applications that propose Phase I and Phase II work in a single submission. If Phase I succeeds, Phase II funding flows without a separate competition. Fast Track reduces the gap between Phase I start and Phase II funding by 12 to 18 months. Not all institutes accept Fast Track; confirm eligibility with the PO before submitting.
Resubmission strategy. If your application is reviewed but not funded, you receive reviewer critiques within weeks of the funding decision. You are allowed one amended submission (A1) with a one-page introduction addressing reviewer concerns. Most successful SBIR awardees received the funding on the A1 submission, not the original. Do not be discouraged by an initial unfunded score — a well-addressed A1 can move your percentile rank dramatically.
SAM.gov and eRA Commons registration — start 6 weeks early. Applications are submitted through Grants.gov, which requires: a valid UEI (Unique Entity Identifier) from SAM.gov, an active SAM.gov registration (annual renewal), and an eRA Commons account for the PI and organization. SAM.gov processing takes 7 to 21 days for new registrants. Registration lapses during the submission window will result in a rejected application. Begin registration at least 6 weeks before your target receipt date.
NIH institutes by therapeutic area
| Your focus area | Primary institute | Also consider |
|---|---|---|
| Oncology / cancer diagnostics | NCI (National Cancer Institute) | NIBIB (imaging devices), NCI SBIR Fast Track |
| Cardiovascular disease / heart failure | NHLBI (Heart, Lung, Blood) | NIDDK (metabolic comorbidities), NIA (aging angle) |
| Neurology / CNS / mental health | NINDS (neurological disorders) | NIMH (psychiatry), NIA (neurodegeneration) |
| Psychiatric / behavioral health | NIMH (Mental Health) | NIDA (substance use), NIAAA (alcohol) |
| Medical devices / imaging | NIBIB (Biomedical Imaging and Bioengineering) | Target disease institute (NCI, NHLBI) for clinical application |
| Infectious disease / antimicrobials | NIAID (Allergy and Infectious Diseases) | NIBIB (rapid diagnostics), NCI (oncology-infection overlap) |
| Diabetes / metabolic disease | NIDDK (Diabetes, Digestive, Kidney) | NHLBI (cardiovascular comorbidities), NCI (obesity-cancer) |
| Rare / orphan diseases | Relevant disease institute + NCATS (translational science) | FDA OOPD for ultra-rare cancer therapeutics specifically |
| Digital health / health IT / AI | NLM (Library of Medicine) | Disease-specific institute if the AI tool targets a specific condition |
SBIR vs STTR for academic spinouts
Use STTR when the founding PI still holds a university appointment and cannot commit more than 50% of working time to the startup. Use SBIR when the PI is fully employed by the company. STTR requires a formal research partnership with a US university or nonprofit hospital — minimum 30% of Phase I work subcontracted to that institution.
The STTR mechanism (R41/R42) was created specifically for the academic spinout problem. In SBIR, the Principal Investigator must be primarily employed — defined as more than 50% of working time — at the small business at the time of award and for the duration of the project. For a faculty member who has not yet taken a leave of absence or reduced their university appointment, this requirement blocks SBIR access.
STTR has no minimum employment requirement for the PI at the small business. The PI can remain primarily employed at the university while leading the project. The tradeoff: STTR mandates a formal research partnership. The small business must subcontract at least 30% of Phase I work to a US-based research institution (accredited university, domestic nonprofit research organization, or FFRDC). The research institution must retain specific intellectual property rights under the collaboration agreement.
The most common STTR bottleneck is not the science — it is the university Technology Transfer Office (TTO). TTOs are chronically understaffed and a first-time STTR collaboration agreement can take 6 to 10 weeks to negotiate and execute. If you are targeting a September 5 receipt date, you need to begin TTO negotiations no later than June 1. Failing to execute the agreement before submission forces a delay to the next cycle.
| Criterion | SBIR | STTR |
|---|---|---|
| PI employment requirement | More than 50% of time at small business | No minimum employment at small business |
| Research institution required | No | Yes — at least 30% of work subcontracted |
| Phase I award cap | $323,090 | $323,090 |
| Phase II award cap | $2,153,927 | $2,153,927 |
| Grant mechanisms | R43 (Phase I) / R44 (Phase II) | R41 (Phase I) / R42 (Phase II) |
| IP rights agreement required | No | Yes — between company and research institution |
| Best for | Founders fully employed by the startup | Academic founders still holding university appointments |
The best choice for an academic founder still on faculty is STTR — not SBIR.
SBIR's greater-than-50%-employment-at-small-business rule blocks most faculty founders until they take formal leave. STTR removes this barrier. The cost: a formal university partnership and 6 to 10 weeks of TTO negotiation. That tradeoff is nearly always worth it for founders who cannot immediately reduce their university appointment.
Timeline: NIH SBIR application to first check
NIH SBIR runs on three fixed receipt dates per fiscal year: September 5, January 5, and April 5. These dates are fixed year-over-year, not subject to program officer discretion. Following submission, the path to first payment takes roughly 9 to 13 months:
- Submission (Day 0): Application submitted through Grants.gov
- Study section review (weeks 8 to 12): Peer review panel scores your application; you receive a percentile rank
- Institute Advisory Council (months 4 to 5): Council reviews applications recommended for funding; meets three times per year (roughly January, May, and September)
- Notice of Award (months 6 to 9): If funded, the institute issues an award letter; negotiations on budget and scope may occur
- First payment (months 9 to 13): Funds flow through the NIH Payment Management System after the award is activated
A September 5 submission under this timeline typically yields a first payment in the following June or July — roughly 10 months later. Fast Track applications shorten this significantly by combining Phase I and Phase II; if Phase I milestones are met, Phase II funding flows without a separate receipt cycle, compressing the total timeline by 12 to 18 months.
Note on the current reauthorization status (May 2026): NIH SBIR and STTR were reauthorized on April 13, 2026. As of May 2026, NIH had not yet published a new omnibus NOFO following reauthorization. The next PHS omnibus solicitation is expected to open several weeks before the September 5, 2026 receipt date. Monitor the NIH SBIR/STTR website and eRA Commons for the new announcement.
NSF SBIR for life-sciences engineering
NSF's America's Seed Fund backs foundational innovation across hard science and engineering domains — including life-sciences engineering. NSF Phase I awards up to $305,000 (slightly below NIH's $323,090) and Phase II up to $1,250,000 (significantly below NIH's $2.15M). Despite the lower ceiling, NSF is the right choice when the primary innovation is an engineering or physical-science breakthrough that enables medical applications, rather than a biological or therapeutic advance itself.
| Innovation type | Better fit | Why |
|---|---|---|
| Novel therapeutic or biologic | NIH (disease institute) | Reviewers understand clinical context; larger Phase II cap |
| Diagnostic device or biosensor | NIH NIBIB or NSF | NIBIB specializes in devices; NSF fits if hardware is the primary innovation |
| AI clinical decision support | NIH NLM or NSF | NLM for clinical data; NSF for AI/ML platform technology |
| Biomanufacturing platform | NSF | Engineering-first; NSF prioritizes manufacturing innovation |
| Medical robotics / surgical tools | NSF or NIH NIBIB | Robotics engineering = NSF; device-plus-clinical validation = NIBIB |
| Wearable / remote monitoring | NIH NIBIB or NSF | Depends whether clinical validation or hardware integration is the bottleneck |
Here's what you need to know about NSF SBIR eligibility: any company majority-owned by a venture capital operating company, hedge fund, or private equity firm is ineligible — full stop. This rule is stricter than DoD or NIH. If a single VC investor owns more than 50% of your company's equity, you cannot apply to NSF SBIR regardless of how technically groundbreaking your work is. This catches many biotech founders off-guard because NIH does not impose a VC ownership restriction. Verify your cap table before investing 100+ hours on an NSF application.
NSF uses a two-stage process. First, submit a 3,500-character Project Pitch online at seedfund.nsf.gov. NSF program directors review pitches and issue invitations to submit full proposals roughly 50% of the time. Only invited applicants can submit full proposals — unsolicited full submissions are returned without review. Of invited proposals, roughly 25% are funded, yielding an overall acceptance rate of approximately 12%. Pre-submission calls with NSF Program Directors are available and materially improve invitation odds.
Note on NSF SBIR current status: NSF paused new Project Pitch submissions on April 16, 2026, citing internal processing delays. The next submission window is expected to reopen in the coming weeks. Monitor seedfund.nsf.gov for the announcement before investing time in a pitch.
FDA cooperative agreements for ultra-rare cancer therapeutics
The FDA's Office of Orphan Products Development funds research through cooperative agreements — a funding mechanism where FDA program staff actively collaborate with and provide regulatory guidance to awardees, rather than passively funding external research. This makes FDA cooperative agreements distinctly valuable for companies navigating the regulatory pathway for rare diseases, where FDA expertise is as valuable as the funding itself.
RFA-FD-26-004 — Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01 mechanism). Awards up to approximately $500,000 per year for 3 years. Open to for-profit companies, biotech, pharma, universities, and nonprofits. Application deadline: June 15, 2026. Ultra-rare cancers affecting fewer than 1,000 US patients.
FDA OOPD cooperative agreements differ from NIH SBIR in three important ways:
- No small business requirement. For-profit companies of any size, universities, nonprofits, and hospitals all compete in the same pool. There is no 500-employee cap or ownership percentage requirement.
- FDA co-investigation. The cooperative agreement (U01) mechanism gives FDA program staff an active role in the research — they review protocols, provide regulatory feedback, and participate in decision points. This is not a passive grant relationship.
- Single-cycle solicitation. Unlike NIH's three-per-year receipt dates, OOPD typically runs one funding cycle per solicitation. Missing the June 15, 2026 deadline means waiting for the next solicitation cycle, which may not open for 12 to 24 months.
The current solicitation targets ultra-rare cancers, typically defined as cancers affecting fewer than 1,000 US patients. This covers pediatric cancers, adult cancers with very small incidence, and certain rare histological subtypes of common cancers. Companies working on novel regulatory and scientific approaches — not just standard drug development — are the target applicant.
FDA OOPD is the right choice for ultra-rare cancer therapeutics — not NIH SBIR.
NIH SBIR for rare cancers goes to NCI study sections staffed with oncology researchers. FDA OOPD cooperative agreements go to OOPD reviewers who understand the FDA regulatory pathway for orphan and ultra-rare diseases and actively participate in guiding your research strategy. For companies working on therapeutics where the FDA pathway is the binding constraint, OOPD's co-investigation model provides regulatory intelligence that NIH cannot. The application deadline of June 15, 2026 is fixed — no extensions are granted for the current cycle.
Expert Deep-Dive: FDA cooperative agreements vs NIH SBIR for ultra-rare therapeutics
When does the FDA pathway fit over NIH SBIR? The answer comes down to the nature of your primary uncertainty. If your primary uncertainty is scientific — does this molecule bind the target, does this device detect the biomarker accurately — then NIH SBIR is the right vehicle. Peer review by disease-area scientists is well suited to evaluate scientific questions. If your primary uncertainty is regulatory — how do we design a trial that FDA will accept as adequate evidence of effectiveness for a disease with fewer than 1,000 patients, where traditional phase III designs are impossible — then FDA OOPD is the right vehicle. OOPD's program staff can provide informal regulatory feedback and actively participate in designing a regulatory strategy that will support an NDA or BLA. This access to FDA expertise is valuable beyond what the grant dollars alone represent.
Cooperative agreement mechanics. A U01 is different from a standard R-mechanism grant. The federal agency has "substantial programmatic involvement" — FDA staff attend project meetings, review study protocols before submission, and can redirect the research scope if early results suggest a more productive path. For companies that have not yet had extensive FDA pre-IND meetings, this built-in regulatory engagement is a meaningful strategic asset.
Pre-application consultations are underused. FDA OOPD holds pre-application consultations for prospective applicants. A 30-minute call with program staff before investing 200+ hours on an application can confirm whether your ultra-rare cancer target and research approach align with OOPD's current scientific priorities. This call is free, voluntary, and cited by funded applicants as one of the most useful preparation steps. Request a consultation via the OOPD website well before the June 15, 2026 deadline.
Application through Grants.gov. Unlike NSF (which uses its own portal), FDA OOPD applications are submitted through Grants.gov, the same platform used for NIH submissions. You need an active SAM.gov registration with a valid UEI, eRA Commons registration for the PI and institution, and an active Grants.gov account. Allow 10 to 14 business days for new SAM.gov registrations — starting this process in late April or early May is advisable for a June 15 submission.
Federal R&D tax credits for biotech companies
The Section 41 Research and Development Tax Credit is often described as a "tax credit," which undersells its relevance to pre-revenue biotech companies. The most important version for early-stage life-sciences founders is the Qualified Small Business payroll-tax offset — a mechanism that converts what would otherwise be a future income-tax credit into real cash against current payroll obligations, even before the company earns its first dollar of profit.
The regular credit rate is 20% of qualified research expenses above your historical base. The Alternative Simplified Credit (ASC) is 14% of QREs above 50% of your three-year average — simpler to calculate, widely used by early-stage companies. Pre-revenue QSBs can offset up to $500,000 per year in payroll taxes using the credit. The IRA (Inflation Reduction Act) doubled this cap from $250,000, effective for tax years beginning after December 31, 2022.
For a pre-revenue biotech company burning $400,000 per year on engineering and research payroll, the Section 41 QSB payroll-tax offset works as follows: the company calculates its qualified research expenses (QREs), claims the ASC credit at 14% above the base, and elects to apply that credit against FICA payroll taxes on Form 941 rather than against future income taxes. The credit effectively reduces the quarterly payroll tax remittances the company owes to the IRS — a real cash reduction, not a deferred asset.
To qualify as a Qualified Small Business (QSB) for the payroll offset, the company must have: (1) gross receipts under $5 million for the current tax year, and (2) no gross receipts for more than five tax years. A biotech company with $0 in revenue and three years of operating history easily qualifies. The election is made on Form 6765 filed with the original tax return by the due date (including extensions).
What counts as a qualified research expense? The Section 41 four-part test defines qualifying research as: technological in nature, aimed at developing or improving a business component, involving genuine uncertainty, and relying on experimentation. For biotech companies, this covers wages for researchers conducting lab work, costs of supplies consumed in experiments, costs paid to contract research organizations for experimental work, and certain computer rental costs for simulations. Legal fees, clinical trial costs in certain phases, patent prosecution costs, and social science research do not qualify.
Section 174 capitalization — the cash-flow wrinkle
Here's what you need to know about Section 174 and its relationship to the Section 41 credit: Section 174 does not eliminate your R&D tax credit, but it does change when your R&D expenses are deducted. Starting January 1, 2022, R&D expenses that were previously deductible in the year incurred must now be capitalized and amortized over 5 years for US-based research (15 years for foreign research). The Section 41 credit is still calculated based on current-year qualified research expenses — the amortization change affects your expense deduction, not the credit calculation. Pre-revenue biotech companies using the QSB payroll-tax offset are partially insulated because the payroll offset is driven by the current-year credit amount, not by deduction timing.
| Parameter | Detail |
|---|---|
| Regular credit rate | 20% of QREs above base period amount |
| ASC rate (simplified) | 14% of QREs above 50% of 3-yr average |
| QSB payroll-tax offset cap | $500,000/year (post-IRA; was $250K before 2023) |
| QSB revenue threshold | Under $5M gross receipts |
| QSB age threshold | No gross receipts for more than 5 tax years |
| Election form | Form 6765 (filed with original return) |
| Payroll offset applied on | Form 941 (quarterly payroll tax filings) |
| Documentation needed | Time records, project logs, expense receipts (contemporaneous) |
Expert Deep-Dive: Building a defensible R&D credit claim for biotech audits
The audit risk is real but manageable. R&D credit claims are audited at an estimated rate of 5 to 10% of filers. When disallowance occurs, it is typically partial — the IRS challenges specific expense categories rather than the entire claim. The most commonly challenged items in biotech are: (1) wages for researchers who also performed non-qualifying activities (e.g., clinical operations, business development, regulatory submissions that are not themselves experimental), (2) contract research organization invoices without adequate documentation of which activities were experimental vs. production, and (3) supply costs for materials used in both qualifying and non-qualifying activities.
Document contemporaneously, not retrospectively. The IRS requirement is for contemporaneous records that identify each project, the employees working on it, the hours spent on qualifying vs. non-qualifying activities, and the nature of the research uncertainty. Time-tracking software, lab notebooks, experimental protocols, and project management records all serve as documentation. Reconstructed records prepared after an audit notice are viewed with suspicion and are significantly weaker than records created during the work.
The four-part test in biotech practice. "Technological in nature" is usually straightforward for biotech — cell biology, molecular biology, chemistry, and bioengineering clearly qualify. "Genuine uncertainty" means uncertainty about whether or how to achieve a specific technical goal — this is almost always present in early-stage biotech. "Experimentation" means the process must rely on trial-and-error or hypothesis testing, not engineering judgment. "Developing or improving a business component" means the research must be aimed at a product, process, technique, invention, formula, or computer software — research aimed at the general advancement of science without a specific commercial application does not qualify under Section 41 (though it may qualify under other NIH grant categories).
Clinical trial costs: the tricky boundary. Pre-clinical research — cell assays, animal studies, formulation development — clearly qualifies. Phase I and II clinical trial costs that are aimed at determining basic safety and proof-of-concept often qualify. Phase III clinical costs aimed at obtaining FDA approval (once the compound's efficacy is established) do not qualify, because they are no longer addressing genuine uncertainty about the technology itself. Many biotech companies under-claim by excluding all clinical trial costs; work with a qualified R&D tax credit specialist to identify the qualifying portion.
State R&D credits with biotech bonuses
The federal Section 41 credit stacks with state R&D tax credits — and in several biotech hubs, state credits include features specifically designed for pre-revenue life-sciences companies that make them unusually powerful. The Massachusetts MLSC refundability provision is the most significant, but California's infinite carryforward and Maryland's job creation credits also deserve attention.
Massachusetts: the MLSC 90% refundable credit
Massachusetts offers a 10% credit on incremental in-state R&D expenses above the historical base (15% for basic research payments to Massachusetts universities). The credit is non-refundable for most companies — unused credits carry forward 15 years. For certified life sciences companies, however, the Massachusetts Life Sciences Center can certify the company to receive 90% of unused credits as a cash refund from the state, rather than a 15-year carryforward.
For a pre-revenue Massachusetts biotech company spending $2,000,000 annually on in-state research, the calculation might look like: 10% credit on incremental expenses above base yields, say, $150,000 in credits per year. As a certified life sciences company, 90% of that — $135,000 — is received as a direct cash payment. Over five years, that amounts to $675,000 in cash that would otherwise have been a non-refundable credit sitting on a balance sheet.
Critical gate: the MA R&D credit is C-corporation only. Most early-stage Massachusetts biotechs are organized as LLCs for VC tax reasons — the pass-through structure allows investors to flow through tax losses to their own returns. But the Massachusetts R&D credit (and the MLSC refundability) is available only to C-corporations and S-corporations. Partnerships and LLCs treated as partnerships are explicitly excluded. A pre-revenue MA biotech LLC that converts to C-corp prior to generating significant R&D expenses can access this credit going forward; expenses incurred as an LLC do not generate retroactive credits.
Expert Deep-Dive: How MA biotech LLCs convert to C-corp to access the MLSC credit
Why the conversion matters. A Delaware LLC treated as a partnership for tax purposes — the standard structure for VC-backed biotech — generates zero Massachusetts R&D credit. The moment the same company converts to a C-corporation and applies for MLSC certification, it begins accruing credits on Massachusetts-located R&D expenses at 10% of incremental expenses. For a company spending $1 to $3 million per year in state on research payroll, supplies, and CRO contracts, this is a material cash difference.
The conversion process. The standard path is an LLC-to-C-corp conversion under Delaware law, which is a straightforward statutory merger. The LLC's existing operating agreement and cap table are replaced by corporate charter documents and a stockholder agreement. Tax counsel coordinates the conversion to preserve federal and state tax attributes and minimize recognition events. Most VC investors prefer C-corp structure for equity investment reasons (easier stock option grants, cleaner Series A documentation), so the conversion often aligns with or precedes the first institutional financing.
MLSC certification timing. MLSC certification can be applied for after conversion. The MLSC reviews applications for life sciences company certification based on the company's R&D activities, employment in Massachusetts, and capital investment. The certification is necessary to access the refundability provision — uncertified C-corps still earn the 10% credit but receive only the standard 15-year carryforward treatment.
University research route. The 15% rate for basic research payments to Massachusetts universities is underused. A $500,000 sponsored research agreement with MIT, Harvard, UMass, or other Massachusetts institutions generates $75,000 in Massachusetts R&D credits compared to roughly $50,000 from the equivalent direct internal expense at the 10% rate. Companies with ongoing academic collaborations should structure them as Massachusetts-based research agreements where possible to capture the higher credit rate.
California: no cap, infinite carryforward
California offers a 15% credit on in-state qualified research expenses above the historical base (24% for payments to California universities and research consortia). There is no annual cap on the credit amount and the carryforward is infinite — unlike most state R&D credits that expire in 5 to 10 years. California's credit is available to any entity type, including LLCs, partnerships, S-corps, and C-corps, making it accessible without a conversion requirement.
| State | Credit Rate | Special Feature | Entity Requirement |
|---|---|---|---|
| Massachusetts | 10% (15% for univ. research) | 90% cash refund for MLSC-certified life sciences companies | C-corp or S-corp only |
| California | 15% (24% for univ. research) | No annual cap; infinite carryforward | Any entity type |
| Maryland | 10% QREs (Basic Research: 10%) | Strong biotech cluster in Baltimore / Frederick corridor | C-corp primarily |
| New York | 6% QREs (9% for facilities) | Excelsior Jobs credit stacks for qualified life sciences companies | C-corp primarily |
| North Carolina | N/A — expired 2015 | RTP cluster supported by federal SBIR and NIH; no state R&D credit | — |
Here's what you need to know about stacking federal and state R&D credits: they are not mutually exclusive. A Massachusetts biotech company claiming the federal Section 41 credit at 14% ASC also claims the Massachusetts credit at 10% on the same expenses. The federal credit reduces federal income tax liability (or provides a payroll offset for QSBs); the Massachusetts credit reduces Massachusetts corporate excise liability or, for MLSC-certified companies, generates a 90% cash refund. The credits are computed on separate tax returns against separate tax bases. Double-counting the same expenses for both credits is permitted and standard practice.
SBA loans for biotech facilities and equipment
Federal grants and tax credits cover R&D expenses. They do not cover the physical infrastructure that R&D requires: laboratory buildouts, biosafety equipment, cold chain storage, cleanroom construction, or research-grade manufacturing space. The SBA 7(a) program — the agency's primary loan guarantee program — fills this gap for companies that cannot access conventional commercial credit on reasonable terms.
The SBA 7(a) program backs loans up to $5,000,000 with an SBA guarantee of 85% on loans of $150,000 or less and 75% on larger loans. The SBA does not lend directly — it guarantees loans made by SBA-approved banks and credit unions, allowing those lenders to extend credit to businesses they would otherwise not finance. Biotech companies are not restricted from the 7(a) program; the primary eligibility requirements are that the business is for-profit, US-based, and meets SBA size standards (typically fewer than 500 employees for life-sciences companies).
For fixed assets — laboratory equipment, property acquisition, and facility construction — the SBA 504 CDC loan program is often a better option than 7(a). The 504 program offers up to $5.5 million (higher in certain industries and regions) specifically for fixed assets, typically at below-market interest rates because of the structure: a conventional first mortgage (50%), a Certified Development Company second mortgage guaranteed by SBA (40%), and equity from the borrower (10%). The 504 structure reduces the borrower's interest expense relative to a 7(a) loan for the same asset.
The single most important tactical advice for SBA 7(a) applications: apply through a Preferred Lender Program (PLP) bank. PLP banks have delegated authority to approve SBA loans in-house without sending the application to the SBA for review. A PLP bank approval can close in 30 to 45 days. A standard 7(a) approval through a non-PLP lender can take 90 to 120 days because the application travels to an SBA loan processing center. The list of PLP lenders is available on the SBA website by geography.
For biotech lab buildouts and equipment, compare SBA 504 first, then 7(a).
SBA 504 is purpose-built for fixed assets and offers lower interest rates through its structure (10% borrower equity, 40% CDC/SBA second mortgage, 50% conventional first mortgage). SBA 7(a) is more flexible — it covers working capital, acquisitions, and debt refinancing that 504 cannot — but at slightly higher effective rates for equivalent fixed-asset financing. For a $2M lab buildout, compare both structures with two or three SBA lenders before committing.
Your funding path by founder type
If you're a first-time biotech founder spinning out of an academic lab
You are in a good position — academic spinouts are one of the strongest SBIR applicant profiles because you have preliminary data, a publication record, and established collaborator relationships. The NIH SBIR system was designed for exactly your situation.
Start with an STTR application rather than SBIR if you are still holding your faculty appointment. The STTR's PI employment flexibility lets you lead the application without having to immediately reduce your university time. Begin TTO negotiations for the collaboration agreement at least 10 weeks before your target receipt date — this is typically the longest lead item, not the writing.
Email the Program Officer at your target institute before writing a word of the application. Describe your technology in three paragraphs. The PO will tell you whether you are in the right institute and whether the project scope fits the current solicitation. This conversation prevents the most common first-timer mistake: writing a strong application for the wrong funding vehicle.
While waiting for SBIR results, work with a qualified tax advisor to document your ongoing R&D expenses for the Section 41 credit. Even if you are not yet paying significant payroll, establishing documentation practices before the company scales saves significant catch-up work later. If you are incorporated as a C-corp in Massachusetts, pursue MLSC certification early.
If you're a medical device startup on the FDA 510(k) pathway
Your primary funding home is NIH NIBIB — the National Institute of Biomedical Imaging and Bioengineering — or NSF SBIR if the innovation is primarily an engineering advance. If your device addresses a specific disease area (cardiovascular imaging at NHLBI, cancer diagnostics at NCI), submit to the disease institute rather than NIBIB.
The 510(k) pathway is relevant to your SBIR application: study sections view 510(k)-eligible devices more favorably than de novo devices because the regulatory pathway is clearer and the commercialization timeline is shorter. Your Phase II commercialization plan should include a realistic 510(k) submission timeline and an analysis of the predicate devices you will rely on.
NSF is worth considering if the device's primary innovation is in the hardware, materials, or manufacturing process rather than the clinical application. NSF reviewers are engineers, not clinicians, and they evaluate technical innovation independent of disease context. If your device has potential applications across multiple medical areas, NSF's broad scope is an advantage.
On the tax side: your engineering team's salaries — design engineers, software developers building the device interface, electrical engineers working on the sensor — are highly likely to qualify as QREs under Section 41. The QSB payroll-tax offset of up to $500,000 per year can materially reduce your quarterly payroll tax burden, especially in years before you close a Series A.
If you're a pre-commercial therapeutics company heading toward pre-IND
You are in the core NIH SBIR target profile. A pre-IND biotech working on a novel therapeutic — small molecule, biologic, gene therapy, cell therapy — is exactly what the NIH SBIR program was built to fund. Phase I covers feasibility and mechanism work; Phase II carries you toward IND-enabling studies.
Your institute selection is the most important decision you will make. Do not simply choose NCI because you are working on a cancer target — determine whether your mechanism, patient population, and scientific approach align more with NCI, NHLBI, NINDS, NIAID, or another institute. The institute's current payline and the composition of the assigned study section matter as much as institute relevance to your disease area.
For ultra-rare cancer therapeutics (fewer than 1,000 US patients), consider the FDA OOPD cooperative agreement in parallel with NIH SBIR. The two programs are not mutually exclusive. OOPD's co-investigation model provides FDA regulatory expertise that NIH cannot offer, and for ultra-rare diseases where traditional trial designs are infeasible, OOPD's regulatory guidance is often the binding constraint on development — more important than the grant dollars themselves.
Start your SAM.gov registration now if you have not already. First-time registrants can take 2 to 3 weeks to process. A lapsed or new registration at submission time results in a rejected application with no recourse before the next receipt date.
If you're a digital health or health-IT SaaS startup
Digital health has access to NIH SBIR funding through the National Library of Medicine (NLM) for clinical informatics and data science tools, through disease-specific institutes for AI applications targeting specific conditions (NIMH for mental health AI, NINDS for neurological condition monitoring), and through NIBIB for platform diagnostic technologies.
NSF SBIR is a strong alternative — particularly for AI/ML platform technologies that address clinical decision support broadly rather than targeting a specific disease. NSF's engineering orientation suits deep-tech AI founders well, and NSF review panels are more comfortable evaluating technical AI innovation than clinical NIH study sections can be.
The Section 41 R&D credit is especially accessible for digital health SaaS companies: software development for internal use generally qualifies when the software involves genuine technical uncertainty, and most clinical AI development fits this definition. Developer salaries, cloud compute costs for training and validation, and contracted ML engineering costs are typical QREs. Pre-revenue digital health companies with significant engineering payroll should be calculating this credit quarterly.
Be aware of NSF's VC-ownership restriction: if your company is majority-owned by a VC fund, you are ineligible for NSF SBIR. This does not affect NIH SBIR eligibility. Many digital health companies that receive seed financing from venture capital before pursuing NSF SBIR discover this restriction too late — verify your cap table before investing time in an NSF pitch.
If you're a pharma or CRO working on ultra-rare cancer programs
You are the target applicant for FDA OOPD cooperative agreements. The current solicitation (RFA-FD-26-004, deadline June 15, 2026) explicitly welcomes for-profit companies including pharma and biotech of any size. There is no small business size requirement, no employee cap, and no VC-ownership restriction.
FDA OOPD cooperative agreements are valuable not only for the funding but for the built-in regulatory access. For ultra-rare cancers where FDA has limited precedent for trial design and efficacy standards, having OOPD program staff actively participate in your research — reviewing protocols, providing informal feedback on regulatory approach, participating in decision points — is a strategic asset that materially reduces your regulatory risk at NDA/BLA stage.
Request a pre-application consultation with OOPD program staff immediately. The June 15 deadline is 5 to 6 weeks away. Consultations typically require 2 to 3 weeks to schedule. A 30-minute conversation confirming your ultra-rare cancer target and regulatory science approach aligns with current OOPD priorities is well worth the time investment before committing 200+ hours to a full application.
The federal Section 41 credit is fully available to pharma companies. Larger companies face a different credit calculation (the regular 20% method requires a complex base period calculation), but the credit is material at any scale. Companies with revenues that disqualify the QSB payroll-tax offset still earn the regular credit against income tax — and the credit carries forward 20 years if not fully used in the current year.
Decision trees: where do you start?
Decision Tree 1 — Which federal grant program fits your company?
IF YES → Go to Q2
IF NO (device, platform, software, engineering) → Go to Q4
IF YES → Go to Q3
IF NO → Consider NCATS (translational science) or FDA OOPD if ultra-rare cancer
IF YES → Consider NIH SBIR (NCI) AND FDA OOPD in parallel — different mechanisms, both accessible
IF NO → Apply to the relevant NIH disease institute via SBIR (R43) or STTR (R41)
IF YES → NSF SBIR is ineligible. Apply to NIH NIBIB or the relevant disease institute via SBIR
IF NO → Go to Q5
IF YES → NSF SBIR is likely your best fit. Submit Project Pitch at seedfund.nsf.gov
IF NO (clinical application is the primary focus) → Apply to NIH NIBIB or disease institute
Decision Tree 2 — Federal §41 credit: which offset strategy fits your company?
IF YES → You are a Qualified Small Business (QSB). Go to Q2
IF NO → You can still claim the Section 41 credit against income tax, but not the payroll-tax offset. Use ASC or regular method with your tax advisor
IF YES → Elect the QSB payroll-tax offset on Form 6765. Offset applies against Form 941 quarterly payroll taxes. Cap: $500K/yr
IF NO (minimal payroll, mostly contractors) → Claim the credit against future income tax; carryforward 20 years. Evaluate whether hiring employees earlier accelerates the credit utility
IF YES → Apply for MLSC life sciences company certification. Earn MA R&D credit at 10% (15% for univ. research); collect 90% as cash refund
IF NO (LLC or out of state) → Check whether conversion to C-corp makes economic sense; evaluate California (15%, any entity type) and other state credits
Decision Tree 3 — SBIR vs STTR for the academic founder
IF YES → SBIR is available. No research institution required. Proceed to standard SBIR application
IF NO (still primarily on faculty) → Go to Q2
IF YES → Apply via STTR (R41). Begin TTO negotiations immediately — allow 8–10 weeks for the collaboration agreement
IF NO → STTR is not available without a qualifying institution partner. Take faculty leave or reduce appointment below 50% to qualify for SBIR
IF YES → Proceed. Structure the collaboration agreement to specify the minimum 30% subcontract; include the IP rights allocation per STTR requirements
IF NO → The institution partnership is a hard requirement. Consider a different partner institution or restructure work scope to meet the threshold
Deeper dives: key questions answered
How do you stack multiple biotech funding sources without conflicts?
NIH SBIR, the federal Section 41 credit, and state R&D credits are fully stackable on the same R&D expenses. The only restriction: you cannot claim the Section 41 credit on the same dollar of expenses you cover with an NIH SBIR grant. Grant-funded expenses are excluded from the QRE pool — but expenses funded by company equity or venture capital are fully eligible. The MA MLSC refundability stacks on top of all of this.
The stacking rules in biotech funding are simpler than most founders expect. Federal grant funds (NIH SBIR, NSF, FDA OOPD) and federal tax credits (Section 41) operate on different portions of your total R&D spending. Expenses reimbursed by a federal grant cannot be claimed as QREs for the Section 41 credit — you cannot get a tax credit on money the government already gave you. But expenses funded by your own capital, investor funds, or operating revenue are fully eligible for Section 41, regardless of whether you also receive federal grant funds for other expenses.
State R&D credits use the same base of expenses as the federal credit (qualified research expenses conducted in the state) but operate on separate tax returns against separate tax bases. The Massachusetts R&D credit does not reduce the federal QRE base and the federal credit does not reduce the Massachusetts credit calculation.
What are the realistic NIH SBIR Phase I spending patterns?
Phase I awards are capped at $323,090 in total costs (direct costs plus indirect costs plus the 7% fee). In practice, most awardees request between $250,000 and $306,872 in total costs. Requests above the cap require prior NIH approval. The 6-month period of performance is typical but can be extended to 12 months with institute approval for projects requiring longer feasibility timelines.
Note: Some older NIH program announcements and some online resources still reference the prior statutory cap of $306,872, which was the SBA limit before the October 2024 update. The current binding cap is $323,090 total costs. If you encounter a reference to $306,872 in a current program announcement, this reflects an outdated citation — the $323,090 limit applies. Requests between $306,872 and $323,090 do not require special justification; requests above $323,090 require prior written NIH approval.
Indirect costs in NIH SBIR applications are reimbursed at your company's negotiated rate or a de facto rate of 26% for organizations without a negotiated rate. Most early-stage biotechs without a Facilities and Administrative (F&A) rate agreement will use the 26% default. The 7% fee is applied to direct costs plus indirect costs and represents a modest profit margin over and above research expenses.
When is the best receipt date to target for NIH SBIR?
For most biotech companies, the September 5 receipt date yields the most competitive applications. It follows the full summer preparation season and precedes fiscal year-end, when institutes are actively looking to commit budget. The January 5 date is the most competitive (submissions from companies who missed September); the April 5 date is the least competitive — fewer submissions, but some institutes have less remaining budget late in the fiscal year.
Here's what you need to know about NIH SBIR receipt date strategy: the "least competitive" submission date is not necessarily the best. Study section review scores are not adjusted for submission date — the same application receives the same score in any cycle. What varies is whether the institute has budget to fund at your percentile rank in that cycle. Late-fiscal-year funding (for April 5 submissions that result in awards) can be constrained because some institutes have already committed most of their annual budget. September 5 submissions are funded from the following fiscal year budget, which is typically the most robust. Talk to the Program Officer about the institute's funding cycle before strategically choosing a receipt date.
Frequently asked questions
What is the NIH SBIR Phase I award amount in 2026?
The SBA statutory cap for NIH SBIR Phase I is $323,090 in total costs (direct costs plus indirect costs plus the 7% fee) as updated in October 2024. Some older NIH program announcements still reference the prior cap of $306,872 — the current binding limit is $323,090. Phase II awards carry a separate cap of $2,153,927 over two years.
What is the realistic timeline from NIH SBIR application to first check?
Plan 9 to 13 months from submission to first payment. A September 5 submission is scored by a study section in November or December, the institute advisory council meets in January, and awards typically issue in spring. Fast Track applications — combining Phase I and II in one submission — shorten this by 12 to 18 months by eliminating the Phase I closeout period before Phase II begins.
What is the difference between NIH SBIR and STTR for academic spinouts?
The key difference is PI employment. In SBIR, the Principal Investigator must be primarily employed — more than 50% of working time — at the small business. In STTR, the PI can remain primarily employed at the university. STTR requires a formal research partner agreement: the small business must subcontract at least 30% of Phase I work to an accredited university, nonprofit hospital, or FFRDC. STTR is designed specifically for academic founders still holding faculty appointments.
How does the federal R&D tax credit Section 41 payroll offset work for pre-revenue biotech companies?
The Inflation Reduction Act doubled the Qualified Small Business payroll-tax offset from $250,000 to $500,000 per year, effective for tax years beginning after December 31, 2022. Pre-revenue biotech companies with no income tax liability can elect to apply up to $500,000 of their annual Section 41 credit against payroll taxes on Form 941 — generating real cash offsets against quarterly payroll obligations before earning any profit. To qualify as a QSB, the company must have gross receipts under $5 million and be in its first five years of having gross receipts.
What is the Massachusetts MLSC 90% refundable R&D credit for biotech companies?
Certified life sciences companies in Massachusetts can receive 90% of unused Massachusetts R&D credits as a direct cash refund from the state. The MA credit is 10% of incremental in-state R&D expenses (15% for basic research payments to Massachusetts universities). Critical requirement: the company must be a C-corporation or S-corporation — LLCs are ineligible. Pre-revenue MA biotechs organized as LLCs must convert to C-corp and then apply for MLSC certification to access this program.
When should a biotech startup apply to NSF SBIR instead of NIH SBIR?
Choose NSF when your technology is primarily an engineering or physical-science innovation — diagnostic devices, biomanufacturing platforms, AI-driven clinical tools, or medical robotics. NSF Phase I awards up to $305,000 (less than NIH's $323,090) and Phase II up to $1,250,000 (well below NIH's $2.15M). Warning: NSF is ineligible for any company majority-owned by a VC, hedge fund, or private equity firm — stricter than NIH.
Can for-profit biotech companies apply for FDA cooperative agreement funding?
Yes. FDA OOPD cooperative agreements (U01 mechanism) explicitly accept for-profit companies, including small biotech and pharma of any size. The current solicitation (RFA-FD-26-004) targets ultra-rare cancers affecting fewer than 1,000 US patients, with awards up to approximately $500,000 per year over three years. There is no small business size requirement and no VC-ownership restriction. Application deadline: June 15, 2026.
What did the Section 174 capitalization change mean for biotech companies?
Starting January 1, 2022, R&D expenses must be capitalized and amortized over 5 years for US-based research (15 years for foreign research) rather than deducted immediately. This does not eliminate the Section 41 credit — you still earn the credit on current-year qualifying expenses. It creates a timing mismatch: deductions occur more slowly while credits accrue based on actual spending. Pre-revenue biotech companies using the QSB payroll-tax offset are partially insulated because the payroll offset is driven by the current-year credit calculation, not by deduction timing.
Can a biotech company use SBA loans for lab facilities or equipment?
Yes. SBA 7(a) loans up to $5,000,000 can finance lab buildouts, equipment purchases, real estate acquisition, and working capital. For fixed assets specifically, compare the SBA 504 CDC program (up to $5.5M for fixed assets, typically better rates) alongside 7(a). Apply through a Preferred Lender Program (PLP) bank to cut approval time from 90 to 120 days down to 30 to 45 days.